Related Experiment Video
Updated: Oct 15, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma
Ching-Ni Njauw1, Zhenyu Ji1, Duc Minh Pham2
1Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
Acral and mucosal melanomas arise from sun-protected sites, disproportionately impact darker-skinned individuals, and exact higher mortality than common types of cutaneous melanoma. Genetically, acral and mucosal melanomas harbor more alterations of KIT than typical cutaneous melanomas. Because KIT-mutated melanomas remain largely treatment resistant, we set out to create a faithful murine KIT-driven allograft model to define newer therapeutic strategies. Using the prevalent human KITK642E activating mutation, the murine mKITK641E cellular avatars show features of transformation in vitro and tumorigenicity in immunocompetent C57BL/6J mice. mKITK641E cells proliferate more rapidly, exhibit greater chromosomal aberrations, and sustain three-dimensional spheroid expansion and aggressive tumor growth in C57BL/6J mice compared with their vector-controlled cells. We further verified the functional dependence of these cells on KITK641E with both genetic and pharmacologic suppression. Using these cells, we performed a screen of 199 kinase inhibitors and identified a selective vulnerability to Chk1/ATR inhibition in the KITK641E-activated cells. Mechanistically, we subsequently showed that KITK641E induces a significantly increased level of replication stress compared with murine vector‒controlled cells. These results showcase an allograft model of human KIT-driven melanomas, which uncovered an unappreciated role for replication stress in KIT melanomagenesis and implicated a possible therapeutic strategy with Chk1/ATR inhibitors.
Insights
Acral and mucosal melanomas are aggressive and linked to KIT mutations. A new mouse model revealed that inhibiting Chk1/ATR may be a viable treatment strategy for these difficult-to-treat melanomas.
Area of Science:
- Oncology
- Dermatology
- Genetics
Background:
- Acral and mucosal melanomas disproportionately affect darker-skinned individuals and have higher mortality rates than cutaneous melanomas.
- These melanomas frequently harbor KIT gene alterations, contributing to treatment resistance.
Purpose of the Study:
- To develop a faithful murine allograft model for KIT-driven melanomas.
- To identify novel therapeutic strategies for KIT-mutated melanomas.
Main Methods:
- Created a murine mKITK641E allograft model using the prevalent human KITK642E mutation.
- Validated the model's transformation and tumorigenicity in immunocompetent mice.
- Screened 199 kinase inhibitors and investigated the mechanistic role of replication stress.
Main Results:
- The mKITK641E model exhibited enhanced proliferation, chromosomal aberrations, and aggressive tumor growth.
- KITK641E activation led to increased replication stress.
- A selective vulnerability to Chk1/ATR inhibition was identified in KITK641E-activated cells.
Conclusions:
- The developed murine model accurately recapitulates human KIT-driven melanomas.
- Replication stress plays a significant role in KIT melanomagenesis.
- Chk1/ATR inhibitors represent a potential therapeutic avenue for KIT-mutated melanomas.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Inhibition of Cdk Activity
DNA Damage Can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
Mitogens and the Cell Cycle
Positive Regulator Molecules

